English
This article is from The Journal of Clinical Endocrinology and Metabolism , volume 99 . Abstract Context:: Coronary artery disease (CAD) is among the leading causes of mortality and morbidity worldwide. Traditional risk markers explain only a proportion of total cardiovascular risk. Thus, development and improvement of early diagnostic strategies and targeted initiation of preventive measures would be of great benefit. Objective:: We aimed to identify molecular lipids that are associated with fatal outcome of CAD patients. Furthermore, the effect of different lipid-lowering drugs on novel risk lipids was evaluated. Methods:: Serum samples of 445 CAD subjects participating in a long-term follow-up of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study were analyzed. In addition, samples obtained from a separate randomized parallel three-group study of subjects treated with simvastatin (n = 24), ezetimibe (n = 24), or their combination (n = 24) were studied. Furthermore, samples from the LURIC participants with a loss-of-function mutation (R46L) in the PCSK9 gene (n = 19) were analyzed and compared with major allele carriers (n = 868). Results:: Distinct ceramide species we
Sign in with your free account to read, download EPUBs or listen.
Ebook · Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency. · Tarasov, Kirill, Ekroos, Kim, Suoniemi, Matti, Kauhanen, Dimple, Sylvanne, Tuulia, Hurme, Reini, Gouni-Berthold, Ioanna, Berthold, Heiner K. · Internet Archive